Drug intelligence / Profile preview

WafeRest

Development stage: Unknown
Lead developer: iX Biopharma
Modality: Small Molecules
Administration: Sublingual

Overview

WafeRest is a sublingual melatonin supplement developed by iX Biopharma using its proprietary WaferiX technology. The product is designed as a fast-dissolving wafer that delivers melatonin directly into the bloodstream via the sublingual mucosa, bypassing first-pass metabolism to potentially improve bioavailability. It is primarily indicated for the alleviation of jet lag and the improvement of sleep quality by regulating the circadian rhythm. As a nutraceutical product, it provides a non-invasive delivery method for melatonin, a hormone naturally produced by the pineal gland that signals the body to prepare for sleep.

Brand names: WafeRest
Other names: Melatonin 6mg ODFMelatonin6mg ODFMelatonin-6mg ODFMelatonin Orally Disintegrating Film

Targets

MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on WafeRest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WafeRest.

Explore the full profile